LEM Surgical AG Secures CHF 22 Million in Series B Funding to Ready Robotic System for FDA Submission

04 Jan 2024
www.biospace.com
BERN, SWITZERLAND / ACCESSWIRE / January 4, 2024 / LEM Surgical AG, an innovative surgical robotics company headquartered in Bern, Switzerland, announces the successful completion of its Series B funding, securing CHF 22 million. The round, which was strongly oversubscribed, reflects the strong investors' confidence in LEM Surgical's differentiated approach. LEM Surgical Logo Company Logo of LEM Surgical This substantial funding boost is attributed to the enthusiastic participation of new investors from both the United States and Switzerland. The infusion of capital is strategically earmarked to propel the advancement of LEM Surgical's product development initiatives and readiness for FDA submission in the second half of 2024. With this latest injection of capital, LEM Surgical is well-positioned to achieve its objectives and to further solidify its potential in the field of surgical robotics. Yossi Bar, founder and CEO of LEM Surgical, expressed the company's vision, stating, "Our goal is to revolutionize the experience for surgeons, clinical teams, and hospitals engaged in robotic surgery. We deeply appreciate the trust and support of our new investors. It underscores the unwavering confidence our investors have in the future success of our groundbreaking technology." About LEM Surgical AG LEM Surgical is at the forefront of shaping the future through the creation of the next generation of robotic surgery platforms. The primary focus of its development efforts is centered around surpassing the capabilities of existing robotic platforms for spine surgery. The company was founded in 2021 by Prof. Dr. Stefan Weber (CEO, CAScination AG), Marco Matulic (CTO, CAScination AG), Simon Michel (CEO, Ypsomed Group), Prof. Dr. Andreas Raabe (Director, Department of Neurosurgery, Inselspital Bern) and Yossi Bar (previously Director R&D at Mazor Robotics Ltd). Follow on LinkedIn Contact Information Yossi Bar Chief Executive Officer communications@lemsurgical.com SOURCE: LEM Surgical AG View the original press release on newswire.com.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
-
Targets
-
Drugs
-
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.